Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
- Daiichi Sankyo Initiates PIII Studies of Mirogabalin in Asia Including Japan
February 5, 2015
- Nipro’s Subsidiary to Build New Factory Eyeing Generic Market Expansion
February 5, 2015
- Wave of Downsizing (3): Mid-Sized Players Muted amid Industry’s Job-Shedding Drive
February 5, 2015
- Belsomra Again Grabs Number 1 Spot in December Anterio Ranking
February 4, 2015
- AbbVie Publishes Japanese PIII Study Results for Hepatitis C Treatment
February 4, 2015
- Astellas to Disclose Detailed Clinical Study Data on Approved Drugs
February 4, 2015
- Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
- Astellas, Osaka University Join Hands in Cell Therapy Research
February 3, 2015
- Sumitomo Dainippon Revving Up “Post-Latuda” Development Drive
February 3, 2015
- 2014 Was “Difficult Year” as Generics Gained Ground: Kyowa Kirin Pres.
February 3, 2015
- Takeda Terminates Development of Combined Quadruple Vaccine
February 3, 2015
- Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
- Drug Price Cuts, Generic Erosion Weigh Kyowa Kirin Earnings
February 2, 2015
- Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy
February 2, 2015
- Astellas Licenses Pollinosis Vaccine from Immunomic Therapeutics
February 2, 2015
- Kyowa Hakko Bio Names Mr Kotani as New President
February 2, 2015
- Chugai to Set Up Global Organization to Bolster Early Clinical Development Functions
January 30, 2015
- Abilify Rakes in US Sales of Nearly US$5 Billion in 2014: Otsuka
January 29, 2015
- Chugai Sales Grow 8.8% Thanks to Increasing Actemra Exports
January 29, 2015
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…